Tag: George D. Yancopoulos

Sanofi, Regeneron get Dupixent EC approval for eosinophilic esophagitis

Raghuram Kadari- February 1, 2023

French pharmaceutical company Sanofi and Regeneron, an American biotechnology company, have received the approval of the European Commission (EC) to market their Dupixent (dupilumab) injection ... Read More

Regeneron Pharmaceuticals begins COVID-19 clinical trials of REGN-COV2

pharmanewsdaily- June 12, 2020

US biotech company Regeneron Pharmaceuticals has started the first clinical trial of its investigational dual antibody cocktail REGN-COV2 (REGN10933+REGN10987) for the prevention and treatment of ... Read More

Dupixent delivers positive results in eosinophilic esophagitis trial

pharmanewsdaily- May 24, 2020

Regeneron Pharmaceuticals and Sanofi said that their co-developed eczema drug Dupixent (dupilumab) has met the co-primary endpoints of Part A of a phase 3 trial ... Read More

Sanofi, Regeneron report Dupixent FDA approval for asthma

pharmanewsdaily- October 21, 2018

Dupixent FDA approval : Dupixent (dupilumab), an eczema drug the co-developed by Sanofi and Regeneron Pharmaceuticals, has been approved by the US Food and Drug Administration ... Read More

Regeneron secures updated label approval from FDA for EYLEA in wet-AMD

pharmanewsdaily- August 19, 2018

The US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) by Regeneron Pharmaceuticals for EYLEA (aflibercept) Injection in patients with ... Read More

Teva, Regeneron report positive data for fasinumab in phase 3 osteoarthritis trial

pharmanewsdaily- August 19, 2018

Teva Pharmaceutical Industries and Regeneron Pharmaceuticals said that a phase 3 study evaluating nerve growth factor (NGF) antibody fasinumab in patients with chronic pain from ... Read More